US FDA approves Biogen-Sage Therapeutics pill for postpartum depression
(Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved Biogen and Sage Therapeutics’ oral pill to treat postpartum depression (PPD) in adults. The companies had sought the FDA’s approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical depression, as well as postpartum depression, which affect millions of people. PPD …
US FDA approves Biogen-Sage Therapeutics pill for postpartum depression Read More »








